StockMacro
Menu

Moderna

$195.00 +315% in 6 monthsMarket cap $78.9B

MRNA on XNAS, Health Care, Moderna, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 772% in a year while the company lost $2.8B and insiders sold $50.8M.

  • BadFree cash flow ran at minus $2B over 12 months
  • GoodNew institutional positions rose to 317, 5.9 times a year earlier

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
4,700
Website
modernatx.com
Listed
Nasdaq, US
Last results
6 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.3B, net income $162.0M.
Quarter to 31 Dec 2021: revenue $7.2B, net income $4.9BQuarter to 31 Dec 2021: revenue $7.2B, net income $4.9BQuarter to 31 Mar 2022: revenue $6.1B, net income $3.7BQuarter to 31 Mar 2022: revenue $6.1B, net income $3.7BQuarter to 30 Jun 2022: revenue $4.7B, net income $2.2BQuarter to 30 Jun 2022: revenue $4.7B, net income $2.2BQuarter to 30 Sep 2022: revenue $3.4B, net income $1.0BQuarter to 30 Sep 2022: revenue $3.4B, net income $1.0BQuarter to 31 Dec 2022: revenue $5.1B, net income $1.5BQuarter to 31 Dec 2022: revenue $5.1B, net income $1.5BQuarter to 31 Mar 2023: revenue $1.9B, net income $79.0MQuarter to 31 Mar 2023: revenue $1.9B, net income $79.0MQuarter to 30 Jun 2023: revenue $344.0M, net income -$1.4BQuarter to 30 Jun 2023: revenue $344.0M, net income -$1.4BQuarter to 30 Sep 2023: revenue $1.8B, net income -$3.6BQuarter to 30 Sep 2023: revenue $1.8B, net income -$3.6BQuarter to 31 Dec 2023: revenue $2.8B, net income $217.0MQuarter to 31 Dec 2023: revenue $2.8B, net income $217.0MQuarter to 31 Mar 2024: revenue $167.0M, net income -$1.2BQuarter to 31 Mar 2024: revenue $167.0M, net income -$1.2BQuarter to 30 Jun 2024: revenue $241.0M, net income -$1.3BQuarter to 30 Jun 2024: revenue $241.0M, net income -$1.3BQuarter to 30 Sep 2024: revenue $1.9B, net income $13.0MQuarter to 30 Sep 2024: revenue $1.9B, net income $13.0MQuarter to 31 Dec 2024: revenue $966.0M, net income -$1.1BQuarter to 31 Dec 2024: revenue $966.0M, net income -$1.1BQuarter to 31 Mar 2025: revenue $108.0M, net income -$971.0MQuarter to 31 Mar 2025: revenue $108.0M, net income -$971.0MQuarter to 30 Jun 2025: revenue $142.0M, net income -$825.0MQuarter to 30 Jun 2025: revenue $142.0M, net income -$825.0MQuarter to 30 Sep 2025: revenue $1.0B, net income -$200.0MQuarter to 30 Sep 2025: revenue $1.0B, net income -$200.0MQuarter to 31 Dec 2025: revenue $678.0M, net income -$826.0MQuarter to 31 Dec 2025: revenue $678.0M, net income -$826.0MQuarter to 31 Mar 2026: revenue $389.0M, net income -$1.3BQuarter to 31 Mar 2026: revenue $389.0M, net income -$1.3BQuarter to 30 Jun 2026: revenue $145.0M, net income -$782.0MQuarter to 30 Jun 2026: revenue $145.0M, net income -$782.0MQuarter to 30 Sep 2026: revenue $1.3B, net income $162.0MQuarter to 30 Sep 2026: revenue $1.3B, net income $162.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $7.2B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.3B$162.0M
30 Jun 2026$145.0M-$782.0M
31 Mar 2026$389.0M-$1.3B
31 Dec 2025$678.0M-$826.0M
30 Sep 2025$1.0B-$200.0M
30 Jun 2025$142.0M-$825.0M
31 Mar 2025$108.0M-$971.0M
31 Dec 2024$966.0M-$1.1B
30 Sep 2024$1.9B$13.0M
30 Jun 2024$241.0M-$1.3B
31 Mar 2024$167.0M-$1.2B
31 Dec 2023$2.8B$217.0M
30 Sep 2023$1.8B-$3.6B
30 Jun 2023$344.0M-$1.4B
31 Mar 2023$1.9B$79.0M
31 Dec 2022$5.1B$1.5B
30 Sep 2022$3.4B$1.0B
30 Jun 2022$4.7B$2.2B
31 Mar 2022$6.1B$3.7B
31 Dec 2021$7.2B$4.9B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.5B $2.2B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$2.8B -$3.1B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$7.10 -$8.07
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 28.0% 48.3% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -116% -155% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -110% -140% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -34.5% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$2.0B -$2.7B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $5.2B $4.5B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $3.5B $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.6B (net cash) -$4.5B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.52 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $16.90
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 31.2 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 30.6 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 11.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ModernaMRNA (this company) $78.9Bloss31.2+13%-110%
BiogenBIIB $36.9B1063.6+2.3%3.4%
Revolution MedicinesRVMD $34.9Bloss–––
Gilead SciencesGILD $206.4Bloss6.7+6.5%-12.5%
AmgenAMGN $235.6B25.16.1+8.2%24.1%
ExelixisEXEL $15.8B17.86.3+9.1%35.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$50.8M

bought $0, sold $50.8M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+35%

1,029 13F filers vs 763

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

77%

310.7M shares held by 13F filers (30 Sep 2026) of 404.6M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.2%

33.2M shares sold short (30 Oct 2026) of 404.6M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.8

33.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.8%

32.6M shares sold short in the report before, 33.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

51%

51% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

241

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+29%

$1.3B vs $1.0B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+42%

$47.0M vs $33.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.4M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

92

92 articles in the last 7 days; its usual week has 10.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.8×

92 articles in the last 7 days; its usual week has 10.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 317, 5.9× a year earlier
  • Page views 18K, 11× a year earlier

Price $195.00 on 20 Nov 2026, +772% over 12 months (12-month range $22.36 to $269.00)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $98.5M in the last 12 months (the 12 months before: $5.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, +150% on the 12 months before.
Revenue per quarter. Revenue $1.3B in the latest quarter, +29% on a year earlier.
Capital spending per quarter. Capital spending $47.0M in the latest quarter, +42% on a year earlier.
Institutional holders (13F filers). 1,029 13F filers reported holding it in the latest 13F quarter, +72% on a year earlier.
Lobbying spend. Lobbying spend: $1.4M published in the last 12 months, +48% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 317 vs usual 72.50 (2026-09-30); 5.9x the same period a year earlier
13 Nov 20268-K and other filingsChief Legal Officer Shannon Thyme Klinger to retire Mar 31, 2027; severance totals $1.6M under retirement agreement
30 Sep 20268-K and other filingsDirector or officer change
25 Aug 2026Sharp changeWikipedia attention spike: wikipedia attention spike, 18K vs usual 1,337 (2026-08-17..2026-08-23); 11.2x the same week a year earlier
8 Jul 20268-K and other filingsDirector or officer change
8 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Apr 2025Lobbying filingnew lobbying registration (HEALTH POLICY SOURCE, INC.)
31 Mar 2025Lobbying filingnew lobbying registration (DGSR LLC)
6 Mar 2025Lobbying filingnew lobbying registration (HOLLAND & KNIGHT LLP)
4 Mar 2025Sharp changeShort interest spike: short interest spike, 42.3M vs usual 24.5M (2025-02-14); 1.8x the same period a year earlier
25 Feb 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 522.0M vs usual 166.5M (2024-12-31); 2.4x the same period a year earlier
18 Feb 2025Sharp changeShort interest spike: short interest spike, 40.6M vs usual 23.4M (2025-01-31); 1.9x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 43.0M vs usual 22.9M (2025-01-15); 1.9x the same period a year earlier
14 Jan 2025Sharp changeShort interest spike: short interest spike, 37.8M vs usual 22.9M (2024-12-31); 1.6x the same period a year earlier
31 Dec 2024Sharp changeShort interest spike: short interest spike, 39.5M vs usual 22.7M (2024-12-13); 1.8x the same period a year earlier
17 Dec 2024Sharp changeShort interest spike: short interest spike, 40.8M vs usual 22.4M (2024-11-29); 1.9x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 39.9M vs usual 22.3M (2024-11-15); 1.8x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 34.4M vs usual 22.2M (2024-10-31); 1.8x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 33.3M vs usual 22.1M (2024-10-15); 1.8x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 31.3M vs usual 22.0M (2024-09-30); 1.7x the same period a year earlier
2 Oct 20248-K and other filingsDirector or officer change
23 Jul 20248-K and other filingsDirector or officer change
23 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jul 2024Sharp changeLobbying on a new issue: lobbying on a new issue: FOR (2024-06-30)
12 Dec 20238-K and other filingsDirector or officer change
12 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Nov 2023Lobbying filingnew lobbying registration (THE WASHINGTON TAX & PUBLIC POLICY GROUP)
31 Oct 2023Lobbying filingnew lobbying registration (in-house)
10 Oct 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 234.0M vs usual 89.0M (2023-06-30); 2.7x the same period a year earlier
10 Oct 2023Sharp changeWikipedia attention spike: wikipedia attention spike, 6,486 vs usual 3,115.50 (2023-10-02..2023-10-08); 1.8x the same week a year earlier
8 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 344.0M vs usual 4.9B (2023-06-30); 0.1x the same period a year earlier
29 Sep 20228-K and other filingsDirector or officer change
17 Aug 20228-K and other filingsDirector or officer change
17 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 May 20228-K and other filingsDirector or officer change
10 May 2022Sharp changeQuarterly revenue change: quarterly revenue change, 6.1B vs usual 1.0B (2022-03-31); 3.1x the same period a year earlier
10 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 132.0M vs usual 19.0M (2022-03-31); 3.8x the same period a year earlier
11 Apr 20228-K and other filingsDirector or officer change
11 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: -$14.7M published
Month from 1 Dec 2021: -$70.4M published
Month from 1 Jan 2022: -$30.9M published
Month from 1 Feb 2022: -$22.6M published
Month from 1 Mar 2022: -$24.8M published
Month from 1 Apr 2022: -$26.0M published
Month from 1 May 2022: -$69.8M published
Month from 1 Jun 2022: -$59.1M published
Month from 1 Jul 2022: -$85.2M published
Month from 1 Aug 2022: -$69.1M published
Month from 1 Sep 2022: -$54.5M published
Month from 1 Oct 2022: -$64.3M published
Month from 1 Nov 2022: -$69.5M published
Month from 1 Dec 2022: -$95.2M published
Month from 1 Jan 2023: -$67.5M published
Month from 1 Feb 2023: -$59.9M published
Month from 1 Mar 2023: -$47.9M published
Month from 1 Apr 2023: -$59.0M published
Month from 1 May 2023: -$41.4M published
Month from 1 Jun 2023: -$50.0M published
Month from 1 Jul 2023: -$14.4M published
Month from 1 Aug 2023: -$6.0M published
Month from 1 Sep 2023: -$9.4M published
Month from 1 Oct 2023: -$4.2M published
Month from 1 Nov 2023: -$778K published
Month from 1 Dec 2023: -$4.7M published
Month from 1 Jan 2024: -$1.6M published
Month from 1 Feb 2024: -$4.8M published
Month from 1 Mar 2024: -$6.8M published
Month from 1 Apr 2024: -$8.0M published
Month from 1 May 2024: -$10.1M published
Month from 1 Jun 2024: -$44.4M published
Month from 1 Jul 2024: -$7.3M published
Month from 1 Aug 2024: -$2.1M published
Month from 1 Sep 2024: -$74K published
Month from 1 Oct 2024: -$43K published
Month from 1 Nov 2024: -$13K published
Month from 1 Dec 2024: -$176K published
Month from 1 Mar 2025: $6.0M published
Month from 1 Jun 2025: -$9K published
Month from 1 Dec 2025: -$717K published
Month from 1 Feb 2026: -$7.8M published
Month from 1 Mar 2026: -$726K published
Month from 1 May 2026: -$3.3M published
Month from 1 Jun 2026: -$2.9M published
Month from 1 Jul 2026: -$3.6M published
Month from 1 Aug 2026: -$28.7M published
Month from 1 Sep 2026: -$16.9M published
Month from 1 Oct 2026: -$17.0M published
Month from 1 Nov 2026: -$16.9M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2026: 5 published
Revenue per quarter
Quarter ended 31 Dec 2021: $7.2B; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $6.1B, +213% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $4.7B, +9.1% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $3.4B, -32% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $5.1B, -29% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $1.9B, -69% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $344.0M, -93% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $1.8B, -46% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $2.8B, -45% on a year earlier; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $167.0M, -91% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $241.0M, -30% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $1.9B, +1.7% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $966.0M, -66% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $108.0M, -35% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $142.0M, -41% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $1.0B, -45% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $678.0M, -30% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $389.0M, +260% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $145.0M, +2.1% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $1.3B, +29% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $132.0M, +277% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $87.0M; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $89.0M, -10% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Mar 2023: $113.0M, -14% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $234.0M, +169% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $140.0M, +57% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $220.0M; public on 24 Feb 2024
Quarter ended 31 Mar 2024: $196.0M, +73% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $182.0M, -22% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $151.0M, +7.9% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $522.0M, +137% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $117.0M, -40% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $3.0M, -98% on a year earlier; public on 2 Aug 2025
Quarter ended 30 Sep 2025: $33.0M, -78% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $39.0M, -93% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $62.0M, -47% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $37.0M, +1133% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $47.0M, +42% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 971; public on 14 Feb 2022
31 Mar 2022 report: 926; public on 16 May 2022
30 Jun 2022 report: 907; public on 15 Aug 2022
30 Sep 2022 report: 822; public on 14 Nov 2022
31 Dec 2022 report: 967; public on 14 Feb 2023
31 Mar 2023 report: 929; public on 15 May 2023
30 Jun 2023 report: 871; public on 14 Aug 2023
30 Sep 2023 report: 804; public on 14 Nov 2023
31 Dec 2023 report: 802; public on 14 Feb 2024
31 Mar 2024 report: 842; public on 15 May 2024
30 Jun 2024 report: 887; public on 14 Aug 2024
30 Sep 2024 report: 728; public on 14 Nov 2024
31 Dec 2024 report: 693; public on 14 Feb 2025
31 Mar 2025 report: 658; public on 15 May 2025
30 Jun 2025 report: 634; public on 14 Aug 2025
30 Sep 2025 report: 600; public on 14 Nov 2025
31 Dec 2025 report: 646; public on 17 Feb 2026
31 Mar 2026 report: 698; public on 15 May 2026
30 Jun 2026 report: 763; public on 14 Aug 2026
30 Sep 2026 report: 1,029; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $130K published
Quarter from 1 Apr 2022: $175K published
Quarter from 1 Jul 2022: $175K published
Quarter from 1 Oct 2022: $165K published
Quarter from 1 Jan 2023: $175K published
Quarter from 1 Apr 2023: $175K published
Quarter from 1 Jul 2023: $175K published
Quarter from 1 Oct 2023: $175K published
Quarter from 1 Jan 2024: $155K published
Quarter from 1 Apr 2024: $195K published
Quarter from 1 Jul 2024: $80K published
Quarter from 1 Oct 2024: $90K published
Quarter from 1 Jan 2025: $170K published
Quarter from 1 Apr 2025: $200K published
Quarter from 1 Jul 2025: $320K published
Quarter from 1 Oct 2025: $280K published
Quarter from 1 Jan 2026: $280K published
Quarter from 1 Apr 2026: $370K published
Quarter from 1 Jul 2026: $490K published
Quarter from 1 Oct 2026: $300K published

What is unusual now

  • Made public in the last 90 days: it saw 317 13F filers open a new position in the quarter ended 30 Sep 2026, 5.9× the same quarter last year; it also drew 18K Wikipedia page views in the week of 17 Aug 2026, 11× the same week last year.
  • Many funds opening a new position: saw 317 13F filers open a new position in the quarter ended 30 Sep 2026, 5.9× the same quarter last year Public on 16 Nov 2026.
  • Wikipedia attention spike: drew 18K Wikipedia page views in the week of 17 Aug 2026, 11× the same week last year Public on 25 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $98.5M in the last 12 months (the 12 months before: $5.8M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 5 sales, $50.8M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Stephen HogePresidentSellplanned in advance (10b5-1); after exercising options78,375$215.63$16.9MForm 4
16 Oct 2026Stephen HogePresidentSellplanned in advance (10b5-1); after exercising options78,369$217.10$17.0MForm 4
16 Sep 2026Stephen HogePresidentSellplanned in advance (10b5-1); after exercising options80,575$145.10$11.7MForm 4
14 Sep 2026James M MockChief Financial OfficerSellplanned in advance (10b5-1); after exercising options34,836$134.49$4.7MForm 4
3 Sep 2026Shannon Thyme KlingerChief Legal OfficerSellplanned in advance (10b5-1); after exercising options3,471$139.95$486KForm 4
7 Aug 2026Stephane BancelChief Executive OfficerSellplanned in advance (10b5-1); after exercising options499,246$57.52$28.7MForm 4
16 Jul 2026Stephen HogePresidentSellplanned in advance (10b5-1); after exercising options53,336$67.60$3.6MForm 4
17 Jun 2026Stephen HogePresidentSellplanned in advance (10b5-1); after exercising options53,336$51.37$2.7MForm 4

1,029 institutions reported shares at the end of Q3 2026, 77% of the shares outstanding; 315 opened a position, 70 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)59.0M14.6%$11.4B+7.1M+14%
BlackRock, Inc.27.8M6.87%$5.4B-2.8M-9.2%
Vanguard Capital Management LLC23.9M5.91%$4.6B+706K+3.0%
Capital World Investors22.6M5.60%$4.4B+362K+1.6%
Vanguard Portfolio Management LLC15.8M3.90%$3.0B+200K+1.3%
State Street Corp15.5M3.82%$3.0B-254K-1.6%
Baillie Gifford & Co11.4M2.83%$2.2B-6.8M-37%
Geode Capital Management, LLC10.2M2.53%$2.0B+534K+5.5%
T. Rowe Price Associates Inc7.6M1.88%+2.0M+36%
Theleme Partners LLP6.7M1.65%$1.3B-1.4M-17%

Company events

All 33 company events

In 12 months: 4 major agreements, 3 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
16 Nov 2026Amended credit agreement with Ares Capital as agent: reduced interest margins by 0.75 points; maturity extended to Nov 24, 2031Same filing: took on new debt8-K
13 Nov 2026Chief Legal Officer Shannon Thyme Klinger to retire Mar 31, 2027; severance totals $1,628,300 under retirement agreement8-K
30 Sep 2026Director or officer change8-K
1 Sep 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
8 Jul 2026Director or officer change8-K
4 Mar 2026Signed a major agreement8-K
24 Nov 2025Signed a major agreementSame filing: took on new debt8-K
2 Oct 2024Director or officer change8-K

241 open postings; careers site tracked since 21 Nov 2026. Most in Research & science 13%, Test, quality & reliability 10%, Manufacturing & production 7%, Operations & administration 5%.

PostedJobLocation
22 Nov 2026Specialist, QMS OperationsOperations & administrationNot stated
22 Nov 2026Senior Manager, Regulatory Intelligence, PharmacopeiaNot stated
22 Nov 2026Manager, QMS OperationsOperations & administrationNot stated
21 Nov 2026or earlierAssociate Director, Stability Lead Development & ClinicalNot stated
21 Nov 2026or earlierSenior GxP Engineer, Endpoint EngineerNot stated
21 Nov 2026or earlierSoftware EngineerSoftware engineeringNot stated
21 Nov 2026or earlierVice President, Human Resources Business PartnerPeople & recruitingNot stated
21 Nov 2026or earlierHead of Translational MedicineNot stated

Reported lobbying spend: $300K in Q3 2026, $490K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
5 Mar 2025NewHolland & Knight LLPfor Moderna, Inc.Tax Reform - Restoring the Orphan Drug Tax Credit.TaxationFiling
15 Feb 2025NewDGSR LLCfor Stanton Park Group LLC On Behalf Of Modernatx, Inc.Issues related to COVID-19 vaccines, mRNA drug discovery, drug development and related issues.Health issuesFiling
1 Dec 2024NewHealth Policy Source, Inc.for Moderna US, Inc.Issues related to vaccines, drug discovery, development and related issues.Medicare/MedicaidFiling
31 Oct 2023NewModerna, Inc.its own lobbyistsMatters affecting the pharmaceutical industryHealth issues, PharmacyFiling
1 Oct 2023NewThe Washington Tax & Public Policy Groupfor Modernatx, Inc.Issues related to corporate and international tax.TaxationFiling
9 Feb 2021NewStanton Park Groupfor Modernatx, Inc.education around potential COVID 19 vaccines and related issuesHealth issuesFiling
9 Feb 2021NewBrownstein Hyatt Farber Schreck, LLPfor Moderna US Inc.Issues related to mRNA drug discovery, drug development, and vaccine technologiesPharmacyFiling
15 Jun 2020NewAvenue Solutionsfor Moderna, Inc.Education around potential COVID-19 vaccines and related issuesHealth issuesFiling

The 5 newest of 1,020 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

25 Feb 2025confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Moderna (MRNA): had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year, while it spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year. Two unrelated kinds of activity within 35 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2025
  • Short interest and volume: Short interest spike, became public on 12 Feb 2025
  • Financials: Quarterly capital spending jump, became public on 25 Feb 2025
  • Short interest and volume: Short interest spike, became public on 27 Feb 2025
2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M
The 15 Jan 2025 report against the 24 reports before it. this reportearliernormal: 22.9M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2025

Moderna had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year.

This period
43.0M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
22.9M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+6.9
Same report last year
23.1M
History used
2,574 days
2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M
the 15 Jan 2025 report24 earlier reportsnormal: 22.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Feb 2025

Moderna had 40.6M shares sold short in the 31 Jan 2025 report, 1.9× the same report last year.

This period
40.6M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
23.4M
Typical spread (median absolute deviation)
2.4M
How far from its usual level
+4.9
Same report last year
20.9M
History used
2,590 days
2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M2025-01-31: 40.6M
the 31 Jan 2025 report24 earlier reportsnormal: 23.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly capital spending jump became public on 25 Feb 2025

Moderna spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.

This period
$522.0M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$166.5M
Typical spread (median absolute deviation)
$41.5M
How far from its usual level
+5.8
Same quarter last year
$220.0M
History used
2,467 days
2022-09-30: $89.0M2023-03-31: $113.0M2023-06-30: $234.0M2023-09-30: $140.0M2023-12-31: $220.0M2024-03-31: $196.0M2024-06-30: $182.0M2024-09-30: $151.0M2024-12-31: $522.0M
the quarter ended 31 Dec 20248 earlier quartersnormal: $166.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 27 Feb 2025

Moderna had 42.3M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.

This period
42.3M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
24.5M
Typical spread (median absolute deviation)
3.3M
How far from its usual level
+3.6
Same report last year
24.1M
History used
2,604 days
2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M2025-01-31: 40.6M2025-02-14: 42.3M
the 14 Feb 2025 report24 earlier reportsnormal: 24.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

10 Oct 2023confirmed

Confirmed across sources Attention and Filings + Financials

Moderna (MRNA): drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year, while it spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year. Two unrelated kinds of activity on the same day.

  • Attention: Wikipedia attention spike, became public on 10 Oct 2023
  • Financials: Quarterly capital spending jump, became public on 10 Oct 2023
2023-04-03: 3,7122023-04-10: 3,6862023-04-17: 3,3462023-04-24: 3,4632023-05-01: 3,3322023-05-08: 3,0042023-05-15: 2,9432023-05-22: 2,9962023-05-29: 2,8552023-06-05: 3,0532023-06-12: 3,0142023-06-19: 2,9382023-06-26: 2,9642023-07-03: 3,0602023-07-10: 2,8282023-07-17: 2,7082023-07-24: 2,9482023-07-31: 3,1712023-08-07: 2,9702023-08-14: 3,4742023-08-21: 3,3322023-08-28: 3,2242023-09-04: 3,4792023-09-11: 4,1792023-09-18: 3,6062023-09-25: 3,4092023-10-02: 6,486
The week of 2 Oct 2023 against the 26 weeks before it. this weekearliernormal: 3,116
See the evidence (2 changes)

Attention: Wikipedia attention spike became public on 10 Oct 2023

Moderna drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year.

This period
6,486 (the week of 2 Oct 2023)
Normal week (median of 26 earlier)
3,116
Typical spread (median absolute deviation)
216
How far from its usual level
+10.5
Same week last year
3,702
History used
1,741 days
2023-04-03: 3,7122023-04-10: 3,6862023-04-17: 3,3462023-04-24: 3,4632023-05-01: 3,3322023-05-08: 3,0042023-05-15: 2,9432023-05-22: 2,9962023-05-29: 2,8552023-06-05: 3,0532023-06-12: 3,0142023-06-19: 2,9382023-06-26: 2,9642023-07-03: 3,0602023-07-10: 2,8282023-07-17: 2,7082023-07-24: 2,9482023-07-31: 3,1712023-08-07: 2,9702023-08-14: 3,4742023-08-21: 3,3322023-08-28: 3,2242023-09-04: 3,4792023-09-11: 4,1792023-09-18: 3,6062023-09-25: 3,4092023-10-02: 6,486
the week of 2 Oct 202326 earlier weeksnormal: 3,116

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Financials: Quarterly capital spending jump became public on 10 Oct 2023

Moderna spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year.

This period
$234.0M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$89.0M
Typical spread (median absolute deviation)
$24.0M
How far from its usual level
+4.1
Same quarter last year
$87.0M
History used
1,917 days
2020-12-31: $23.3M2021-03-31: $35.0M2021-09-30: $99.0M2022-03-31: $132.0M2022-06-30: $87.0M2022-09-30: $89.0M2023-03-31: $113.0M2023-06-30: $234.0M
the quarter ended 30 Jun 20237 earlier quartersnormal: $89.0M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

24 Nov 2020confirmed

Confirmed across sources Attention and Filings + Financials

Moderna (MRNA): reported revenue of $157.9M for the quarter ended 30 Sep 2020, 9.3× the same quarter last year, while it drew 269K Wikipedia page views in the week of 16 Nov 2020, 722× the same week last year. Two unrelated kinds of activity within 21 days.

  • Financials: Quarterly revenue change, became public on 3 Nov 2020
  • Attention: Wikipedia attention spike, became public on 24 Nov 2020
2018-09-30: $41.8M2018-12-31: $35.4M2019-03-31: $16.0M2019-06-30: $13.1M2019-09-30: $17.0M2019-12-31: $14.1M2020-03-31: $8.4M2020-06-30: $66.4M2020-09-30: $157.9M
The quarter ended 30 Sep 2020 against the 8 quarters before it. this quarterearliernormal: $16.5M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 3 Nov 2020

Moderna reported revenue of $157.9M for the quarter ended 30 Sep 2020, 9.3× the same quarter last year.

This period
$157.9M (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
$16.5M
Typical spread (median absolute deviation)
$5.8M
How far from its usual level
+16.4
Same quarter last year
$17.0M
History used
1,279 days
2018-09-30: $41.8M2018-12-31: $35.4M2019-03-31: $16.0M2019-06-30: $13.1M2019-09-30: $17.0M2019-12-31: $14.1M2020-03-31: $8.4M2020-06-30: $66.4M2020-09-30: $157.9M
the quarter ended 30 Sep 20208 earlier quartersnormal: $16.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Attention: Wikipedia attention spike became public on 24 Nov 2020

Moderna drew 269K Wikipedia page views in the week of 16 Nov 2020, 722× the same week last year.

This period
269K (the week of 16 Nov 2020)
Normal week (median of 26 earlier)
11K
Typical spread (median absolute deviation)
4,325
How far from its usual level
+40.2
Same week last year
372
History used
691 days
2020-05-18: 156K2020-05-25: 14K2020-06-01: 8,5722020-06-08: 11K2020-06-15: 9,1202020-06-22: 6,5572020-06-29: 7,3352020-07-06: 6,3212020-07-13: 78K2020-07-20: 19K2020-07-27: 73K2020-08-03: 44K2020-08-10: 32K2020-08-17: 12K2020-08-24: 32K2020-08-31: 14K2020-09-07: 11K2020-09-14: 11K2020-09-21: 6,5102020-09-28: 7,0702020-10-05: 5,3032020-10-12: 5,2812020-10-19: 6,6472020-10-26: 7,6372020-11-02: 3,4712020-11-09: 16K2020-11-16: 269K
the week of 16 Nov 202026 earlier weeksnormal: 11K

Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

Check it at the source: Wikimedia page view statistics.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 317 13F filers open a new position in the quarter ended 30 Sep 2026, 5.9× the same quarter last year.

    Same quarter last year: 54; its normal quarter is 72.5.

    See the evidence
    This period
    317 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    72.5
    Typical spread (median absolute deviation)
    11.5
    How far from its usual level
    +14.3
    Same quarter last year
    54
    History used
    2,830 days
    2024-09-30: 512024-12-31: 742025-03-31: 692025-06-30: 712025-09-30: 542025-12-31: 772026-03-31: 1202026-06-30: 1252026-09-30: 317
    the quarter ended 30 Sep 20268 earlier quartersnormal: 72.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 13 Nov 2026Filings record

    Chief Legal Officer Shannon Thyme Klinger to retire Mar 31, 2027; severance totals $1.6M under retirement agreement

  3. 30 Sep 2026Filings record

    Director or officer change

  4. 25 Aug 2026Attention change

    drew 18K Wikipedia page views in the week of 17 Aug 2026, 11× the same week last year.

    Same week last year: 1,580; its normal week is 1,337.

    See the evidence
    This period
    18K (the week of 17 Aug 2026)
    Normal week (median of 26 earlier)
    1,337
    Typical spread (median absolute deviation)
    137
    How far from its usual level
    +80.9
    Same week last year
    1,580
    History used
    2,791 days
    2026-02-16: 2,2542026-02-23: 1,4092026-03-02: 1,3992026-03-09: 1,3622026-03-16: 1,3272026-03-23: 1,2562026-03-30: 1,2382026-04-06: 1,3472026-04-13: 1,3742026-04-20: 1,6142026-04-27: 1,3092026-05-04: 2,3752026-05-11: 2,0322026-05-18: 1,4282026-05-25: 1,2472026-06-01: 1,6832026-06-08: 1,1682026-06-15: 1,2322026-06-22: 1,1192026-06-29: 9262026-07-06: 1,1092026-07-13: 9532026-07-20: 8732026-07-27: 1,7452026-08-03: 1,9622026-08-10: 1,2362026-08-17: 18K
    the week of 17 Aug 202626 earlier weeksnormal: 1,337

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  5. 8 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 8 Jul 2026Filings record

    Director or officer change

  7. 11 Feb 2026Institutional holdings record

    Capital World Investors opened a $378.0M position (2025Q4 13F)

  8. 10 Apr 2025Lobbying record

    MODERNA US, INC.: new lobbying registration (HEALTH POLICY SOURCE, INC.) (dated 1 Dec 2024)

  9. 31 Mar 2025Lobbying record

    STANTON PARK GROUP LLC ON BEHALF OF MODERNATX, INC.: new lobbying registration (DGSR LLC) (dated 15 Feb 2025)

  10. 6 Mar 2025Lobbying record

    MODERNA, INC.: new lobbying registration (HOLLAND & KNIGHT LLP) (dated 5 Mar 2025)

  11. 5 Mar 2025Insiders record

    SAGAN PAUL (director) bought 31,620 shares of MRNA ($1.0M) (dated 4 Mar 2025)

  12. 5 Mar 2025Insiders record

    Bancel Stephane (Chief Executive Officer) bought 160,314 shares of MRNA ($5.0M) (dated 4 Mar 2025)

  13. 27 Feb 2025Short interest and volume change

    had 42.3M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.

    Same report last year: 24.1M; its normal report is 24.5M.

    See the evidence
    This period
    42.3M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    24.5M
    Typical spread (median absolute deviation)
    3.3M
    How far from its usual level
    +3.6
    Same report last year
    24.1M
    History used
    2,604 days
    2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M2025-01-31: 40.6M2025-02-14: 42.3M
    the 14 Feb 2025 report24 earlier reportsnormal: 24.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 25 Feb 2025several at once

    had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year, while it spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year. Two unrelated kinds of activity within 35 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 28 Jan 2025

    Moderna had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year.

    This period
    43.0M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    22.9M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +6.9
    Same report last year
    23.1M
    History used
    2,574 days
    2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M
    the 15 Jan 2025 report24 earlier reportsnormal: 22.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Feb 2025

    Moderna had 40.6M shares sold short in the 31 Jan 2025 report, 1.9× the same report last year.

    This period
    40.6M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    23.4M
    Typical spread (median absolute deviation)
    2.4M
    How far from its usual level
    +4.9
    Same report last year
    20.9M
    History used
    2,590 days
    2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M2025-01-31: 40.6M
    the 31 Jan 2025 report24 earlier reportsnormal: 23.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly capital spending jump became public on 25 Feb 2025

    Moderna spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.

    This period
    $522.0M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $166.5M
    Typical spread (median absolute deviation)
    $41.5M
    How far from its usual level
    +5.8
    Same quarter last year
    $220.0M
    History used
    2,467 days
    2022-09-30: $89.0M2023-03-31: $113.0M2023-06-30: $234.0M2023-09-30: $140.0M2023-12-31: $220.0M2024-03-31: $196.0M2024-06-30: $182.0M2024-09-30: $151.0M2024-12-31: $522.0M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $166.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 27 Feb 2025

    Moderna had 42.3M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.

    This period
    42.3M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    24.5M
    Typical spread (median absolute deviation)
    3.3M
    How far from its usual level
    +3.6
    Same report last year
    24.1M
    History used
    2,604 days
    2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M2025-01-31: 40.6M2025-02-14: 42.3M
    the 14 Feb 2025 report24 earlier reportsnormal: 24.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 25 Feb 2025Financials change

    spent $522.0M on capital projects in the quarter ended 31 Dec 2024, 2.4× the same quarter last year.

    Same quarter last year: $220.0M; its normal quarter is $166.5M.

    See the evidence
    This period
    $522.0M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $166.5M
    Typical spread (median absolute deviation)
    $41.5M
    How far from its usual level
    +5.8
    Same quarter last year
    $220.0M
    History used
    2,467 days
    2022-09-30: $89.0M2023-03-31: $113.0M2023-06-30: $234.0M2023-09-30: $140.0M2023-12-31: $220.0M2024-03-31: $196.0M2024-06-30: $182.0M2024-09-30: $151.0M2024-12-31: $522.0M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $166.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  16. 12 Feb 2025Short interest and volume change

    had 40.6M shares sold short in the 31 Jan 2025 report, 1.9× the same report last year.

    Same report last year: 20.9M; its normal report is 23.4M.

    See the evidence
    This period
    40.6M (the 31 Jan 2025 report)
    Normal report (median of 24 earlier)
    23.4M
    Typical spread (median absolute deviation)
    2.4M
    How far from its usual level
    +4.9
    Same report last year
    20.9M
    History used
    2,590 days
    2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M2025-01-31: 40.6M
    the 31 Jan 2025 report24 earlier reportsnormal: 23.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 28 Jan 2025Short interest and volume change

    had 43.0M shares sold short in the 15 Jan 2025 report, 1.9× the same report last year.

    Same report last year: 23.1M; its normal report is 22.9M.

    See the evidence
    This period
    43.0M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    22.9M
    Typical spread (median absolute deviation)
    2.0M
    How far from its usual level
    +6.9
    Same report last year
    23.1M
    History used
    2,574 days
    2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M2025-01-15: 43.0M
    the 15 Jan 2025 report24 earlier reportsnormal: 22.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 14 Jan 2025Short interest and volume change

    had 37.8M shares sold short in the 31 Dec 2024 report, 1.6× the same report last year.

    Same report last year: 24.2M; its normal report is 22.9M.

    See the evidence
    This period
    37.8M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    22.9M
    Typical spread (median absolute deviation)
    1.9M
    How far from its usual level
    +5.4
    Same report last year
    24.2M
    History used
    2,559 days
    2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M2024-12-31: 37.8M
    the 31 Dec 2024 report24 earlier reportsnormal: 22.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 25 Dec 2024Short interest and volume change

    had 39.5M shares sold short in the 13 Dec 2024 report, 1.8× the same report last year.

    Same report last year: 21.9M; its normal report is 22.7M.

    See the evidence
    This period
    39.5M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    22.7M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +7.3
    Same report last year
    21.9M
    History used
    2,541 days
    2023-12-15: 21.9M2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M2024-12-13: 39.5M
    the 13 Dec 2024 report24 earlier reportsnormal: 22.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 11 Dec 2024Short interest and volume change

    had 40.8M shares sold short in the 29 Nov 2024 report, 1.9× the same report last year.

    Same report last year: 22.0M; its normal report is 22.4M.

    See the evidence
    This period
    40.8M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    22.4M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +8.2
    Same report last year
    22.0M
    History used
    2,527 days
    2023-11-30: 22.0M2023-12-15: 21.9M2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M2024-11-29: 40.8M
    the 29 Nov 2024 report24 earlier reportsnormal: 22.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 27 Nov 2024Short interest and volume change

    had 39.9M shares sold short in the 15 Nov 2024 report, 1.8× the same report last year.

    Same report last year: 22.4M; its normal report is 22.3M.

    See the evidence
    This period
    39.9M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    22.3M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +7.9
    Same report last year
    22.4M
    History used
    2,513 days
    2023-11-15: 22.4M2023-11-30: 22.0M2023-12-15: 21.9M2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M2024-11-15: 39.9M
    the 15 Nov 2024 report24 earlier reportsnormal: 22.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 13 Nov 2024Short interest and volume change

    had 34.4M shares sold short in the 31 Oct 2024 report, 1.8× the same report last year.

    Same report last year: 19.6M; its normal report is 22.2M.

    See the evidence
    This period
    34.4M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    22.2M
    Typical spread (median absolute deviation)
    997K
    How far from its usual level
    +5.5
    Same report last year
    19.6M
    History used
    2,498 days
    2023-10-31: 19.6M2023-11-15: 22.4M2023-11-30: 22.0M2023-12-15: 21.9M2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M2024-10-31: 34.4M
    the 31 Oct 2024 report24 earlier reportsnormal: 22.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 25 Oct 2024Short interest and volume change

    had 33.3M shares sold short in the 15 Oct 2024 report, 1.8× the same report last year.

    Same report last year: 18.1M; its normal report is 22.1M.

    See the evidence
    This period
    33.3M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    22.1M
    Typical spread (median absolute deviation)
    997K
    How far from its usual level
    +5.0
    Same report last year
    18.1M
    History used
    2,482 days
    2023-10-13: 18.1M2023-10-31: 19.6M2023-11-15: 22.4M2023-11-30: 22.0M2023-12-15: 21.9M2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M2024-10-15: 33.3M
    the 15 Oct 2024 report24 earlier reportsnormal: 22.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 10 Oct 2024Short interest and volume change

    had 31.3M shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.

    Same report last year: 18.5M; its normal report is 22.0M.

    See the evidence
    This period
    31.3M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    22.0M
    Typical spread (median absolute deviation)
    997K
    How far from its usual level
    +4.2
    Same report last year
    18.5M
    History used
    2,467 days
    2023-09-29: 18.5M2023-10-13: 18.1M2023-10-31: 19.6M2023-11-15: 22.4M2023-11-30: 22.0M2023-12-15: 21.9M2023-12-29: 24.2M2024-01-12: 23.1M2024-01-31: 20.9M2024-02-15: 24.1M2024-02-29: 22.1M2024-03-15: 22.2M2024-03-28: 21.4M2024-04-15: 21.0M2024-04-30: 21.1M2024-05-15: 21.4M2024-05-31: 20.2M2024-06-14: 21.6M2024-06-28: 22.1M2024-07-15: 22.7M2024-07-31: 22.6M2024-08-15: 25.0M2024-08-30: 25.6M2024-09-13: 27.6M2024-09-30: 31.3M
    the 30 Sep 2024 report24 earlier reportsnormal: 22.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 2 Oct 2024Filings record

    Director or officer change

  26. 23 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 23 Jul 2024Filings record

    Director or officer change

  28. 16 Jul 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['FOR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6410262
  29. 12 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 12 Dec 2023Filings record

    Director or officer change

  31. 7 Nov 2023Lobbying record

    MODERNATX, INC.: new lobbying registration (THE WASHINGTON TAX & PUBLIC POLICY GROUP) (dated 1 Oct 2023)

  32. 31 Oct 2023Lobbying record

    MODERNA, INC.: new lobbying registration (in-house)

  33. 10 Oct 2023several at once

    drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year, while it spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year. Two unrelated kinds of activity on the same day.

    See the evidence (2 changes)

    Attention: Wikipedia attention spike became public on 10 Oct 2023

    Moderna drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year.

    This period
    6,486 (the week of 2 Oct 2023)
    Normal week (median of 26 earlier)
    3,116
    Typical spread (median absolute deviation)
    216
    How far from its usual level
    +10.5
    Same week last year
    3,702
    History used
    1,741 days
    2023-04-03: 3,7122023-04-10: 3,6862023-04-17: 3,3462023-04-24: 3,4632023-05-01: 3,3322023-05-08: 3,0042023-05-15: 2,9432023-05-22: 2,9962023-05-29: 2,8552023-06-05: 3,0532023-06-12: 3,0142023-06-19: 2,9382023-06-26: 2,9642023-07-03: 3,0602023-07-10: 2,8282023-07-17: 2,7082023-07-24: 2,9482023-07-31: 3,1712023-08-07: 2,9702023-08-14: 3,4742023-08-21: 3,3322023-08-28: 3,2242023-09-04: 3,4792023-09-11: 4,1792023-09-18: 3,6062023-09-25: 3,4092023-10-02: 6,486
    the week of 2 Oct 202326 earlier weeksnormal: 3,116

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

    Financials: Quarterly capital spending jump became public on 10 Oct 2023

    Moderna spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year.

    This period
    $234.0M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 7 earlier)
    $89.0M
    Typical spread (median absolute deviation)
    $24.0M
    How far from its usual level
    +4.1
    Same quarter last year
    $87.0M
    History used
    1,917 days
    2020-12-31: $23.3M2021-03-31: $35.0M2021-09-30: $99.0M2022-03-31: $132.0M2022-06-30: $87.0M2022-09-30: $89.0M2023-03-31: $113.0M2023-06-30: $234.0M
    the quarter ended 30 Jun 20237 earlier quartersnormal: $89.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  34. 10 Oct 2023Financials change

    spent $234.0M on capital projects in the quarter ended 30 Jun 2023, 2.7× the same quarter last year.

    Same quarter last year: $87.0M; its normal quarter is $89.0M.

    See the evidence
    This period
    $234.0M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 7 earlier)
    $89.0M
    Typical spread (median absolute deviation)
    $24.0M
    How far from its usual level
    +4.1
    Same quarter last year
    $87.0M
    History used
    1,917 days
    2020-12-31: $23.3M2021-03-31: $35.0M2021-09-30: $99.0M2022-03-31: $132.0M2022-06-30: $87.0M2022-09-30: $89.0M2023-03-31: $113.0M2023-06-30: $234.0M
    the quarter ended 30 Jun 20237 earlier quartersnormal: $89.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 10 Oct 2023Attention change

    drew 6,486 Wikipedia page views in the week of 2 Oct 2023, 1.8× the same week last year.

    Same week last year: 3,702; its normal week is 3,116.

    See the evidence
    This period
    6,486 (the week of 2 Oct 2023)
    Normal week (median of 26 earlier)
    3,116
    Typical spread (median absolute deviation)
    216
    How far from its usual level
    +10.5
    Same week last year
    3,702
    History used
    1,741 days
    2023-04-03: 3,7122023-04-10: 3,6862023-04-17: 3,3462023-04-24: 3,4632023-05-01: 3,3322023-05-08: 3,0042023-05-15: 2,9432023-05-22: 2,9962023-05-29: 2,8552023-06-05: 3,0532023-06-12: 3,0142023-06-19: 2,9382023-06-26: 2,9642023-07-03: 3,0602023-07-10: 2,8282023-07-17: 2,7082023-07-24: 2,9482023-07-31: 3,1712023-08-07: 2,9702023-08-14: 3,4742023-08-21: 3,3322023-08-28: 3,2242023-09-04: 3,4792023-09-11: 4,1792023-09-18: 3,6062023-09-25: 3,4092023-10-02: 6,486
    the week of 2 Oct 202326 earlier weeksnormal: 3,116

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  36. 8 Aug 2023Financials change

    reported revenue of $344.0M for the quarter ended 30 Jun 2023, 93% below the same quarter last year.

    Same quarter last year: $4.7B; its normal quarter is $4.9B.

    See the evidence
    This period
    $344.0M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $4.9B
    Typical spread (median absolute deviation)
    $856.0M
    How far from its usual level
    -3.6
    Same quarter last year
    $4.7B
    History used
    2,282 days
    2021-06-30: $4.4B2021-09-30: $5.0B2021-12-31: $7.2B2022-03-31: $6.1B2022-06-30: $4.7B2022-09-30: $3.4B2022-12-31: $5.1B2023-03-31: $1.9B2023-06-30: $344.0M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $4.9B

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  37. 29 Sep 2022Filings record

    Director or officer change

  38. 17 Aug 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 17 Aug 2022Filings record

    Director or officer change

  40. 11 May 2022Filings record

    Director or officer change

Showing the newest 40 of 95 entries; narrow the window or the kind of data to see older ones.

Not listed: 925 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001682852
Ticker
MRNA
Domain
modernatx.com
Employer name
Moderna, Inc., moderna services, Moderna US, Inc. (3 unverified)
Hq location
MA|CAMBRIDGE|02142 (1 unverified)
Lobbying client
moderna, moderna us, stanton park group llc on behalf of modernatx
Name
Moderna Australia Pty Ltd, Moderna Biopharma Canada Corporation, Moderna Biotech Distributor UK Ltd, Moderna Biotech Manufacturing UK Ltd and 27 more
Uei
LCY4PQS5SV44
Wikidata
Q17081612
Wikipedia
Moderna
  • DOL H-1B labor condition applications and PERM certifications235 data points16 Dec 2019 to 10 Aug 2026
  • Federal lobbying disclosures (LDA)10 records, 89 data points30 Jun 2019 to 30 Sep 2026
  • SEC Form 13F institutional holdings2 records, 288 data points31 Dec 2018 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)118 records24 Aug 2016 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)653 data points31 Dec 2015 to 30 Oct 2026
  • SEC Form 4 insider transactions833 records, 1996 data points18 Sep 2019 to 18 Nov 2026
  • FINRA short interest (twice monthly)611 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4000 data points7 Dec 2018 to 20 Nov 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026